Diabetes & metabolism最新文献

{"title":"Views and understanding of metabolic dysfunction-associated steatotic liver disease in patients with diabetes","authors":"David M Williams , Jagadish Nagaraj , Laura Wilkinson , Jeffrey W Stephens , Thinzar Min","doi":"10.1016/j.diabet.2026.101723","DOIUrl":"10.1016/j.diabet.2026.101723","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101723"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silent reflux underlying GLP-1RA–associated chronic cough","authors":"Huijun Zheng , Lijuan Ma , Hao Liu","doi":"10.1016/j.diabet.2026.101739","DOIUrl":"10.1016/j.diabet.2026.101739","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101739"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing the role of GLP-1 receptor agonists in colorectal cancer Care","authors":"Baodong Wang ,&nbsp;Jiayuan Huang ,&nbsp;Zhiyun Chen","doi":"10.1016/j.diabet.2026.101742","DOIUrl":"10.1016/j.diabet.2026.101742","url":null,"abstract":"<div><div>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in type 2 diabetes, yet their management after colorectal cancer diagnosis remains uncertain. A recent population-based cohort study reported lower mortality and fewer metastatic events among GLP-1 RA users than among patients receiving other glucose-lowering therapies. However, causal inference is limited by potential immortal time bias from the exposure definition, incomplete reporting of key prognostic and treatment factors (stage, surgery, systemic therapy, performance status), and unclear cohort entry and follow-up windows. In addition, reliance on routine administrative codes may misclassify outcomes. Time-varying exposure models, active-comparator new-user or landmark designs, and registry linkage/validation would strengthen the evidence.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101742"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146207150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV","authors":"Nadia Valin ,&nbsp;Pauline Campa ,&nbsp;Thibault Chiarabini ,&nbsp;Joëlle Michot ,&nbsp;Carole Collet-Gaudillat ,&nbsp;Stéphanie Kury Paulin ,&nbsp;Jacqueline Capeau ,&nbsp;Karine Lacombe","doi":"10.1016/j.diabet.2026.101744","DOIUrl":"10.1016/j.diabet.2026.101744","url":null,"abstract":"<div><div>We report two cases of normoglycemic people with HIV well-controlled by antiretroviral therapy who were switched to a dual long-acting therapy consisting of cabotegravir (CAB), an integrase strand transfer inhibitor, and rilpivirine (RIL), a non-nucleoside analog reverse transcriptase inhibitor, administred intramuscularly once a month then every two months. Both cases developed shortly acute severe hyperglycemia with ketoacidosis or insulinopenia requiring intravenous insulin therapy. Anti-pancreatic autoantibodies were absent. The hyperglycemic episode resumed after stopping CAB/RIL and/or initiating metformin. To our knowledge these are the first reported cases of severe CAB/RIL-induced hyperglycemia. Up to now, long-acting CAB/RIL has not been associated with metabolic outcomes. These cases serve as a warning to clinicians to monitor glycemia when initiating long-acting CAB/RIL therapy.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101744"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147346186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Realizing a vision to improve access to diabetes care","authors":"Cathy J. Sun ,&nbsp;Valérie Savard ,&nbsp;Cindye Audet ,&nbsp;Rémi Rabasa-Lhoret","doi":"10.1016/j.diabet.2026.101746","DOIUrl":"10.1016/j.diabet.2026.101746","url":null,"abstract":"<div><div>Amidst the worldwide physician shortage, we share how realizing our vision can improve access to diabetes care. Central to this vision is a methodical process to assess each patient’s complexity in order to delegate their care within a medically-supervised interdisciplinary comprehensive care clinic.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101746"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bedside amputation surgery for isolated toe necrosis in diabetes units as an alternative to conventional amputation in surgery units","authors":"Florine Féron ,&nbsp;Jean-Philippe Kevorkian ,&nbsp;Jean-Baptiste Julla ,&nbsp;Nadjet Ghozlane ,&nbsp;Serge Aho Glele ,&nbsp;Coralie Fourmont ,&nbsp;Jean-Michel Petit ,&nbsp;Jean-François Gautier ,&nbsp;Mathilde Didier ,&nbsp;Benjamin Bouillet","doi":"10.1016/j.diabet.2026.101727","DOIUrl":"10.1016/j.diabet.2026.101727","url":null,"abstract":"<div><h3>Aim</h3><div>Toe necrosis is a common complication of diabetic foot ulcer (DFU). Amputation surgery is usually performed by a surgeon in the operating room. In response to the limited availability of operating rooms, clinicians from two specialized diabetic foot units performed bedside surgery to amputate isolated toe-necrosis-complicated DFU.</div><div>The aim of our study was to compare the rate of wound healing 6 months after toe amputation following bedside amputation surgery (BAS) and conventional amputation surgery (CAS).</div></div><div><h3>Methods</h3><div>This retrospective observational multi-center study was conducted in two French diabetic foot units. All patients with diabetes mellitus (DM) who underwent a toe amputation for isolated necrosis in an operating room (CAS) or at bedside (BAS) were included (05/2016 – 07/2023). The primary endpoint was the 6-month healing rate, defined as a complete skin epithelialization without recurrence at 6 months, without secondary amputation.</div></div><div><h3>Results</h3><div>Out of 2029 patients admitted for DFU, 189 had isolated toe necrosis requiring limited amputation (9%). Among the 171 patients who attended follow-up at 6 months: males 82.5%, type 2 DM 94.7%, average duration of DM 18.3 ± 0.9years, average HbA1c 8.6 ± 2%. BAS was performed on 106/171(62%) patients. The 6-month healing rate was not significantly different between the two groups (BAS 53.8% vs CAS 52.3%, <em>P</em> = 0.852). The rate of secondary surgery was not significantly different (BAS 24.5% vs CAS 16.9%, <em>P</em> = 0.241).</div></div><div><h3>Conclusion</h3><div>BAS is a safe and efficient approach for the treatment of isolated toe necrosis, resulting in a healing rate similar to that of conventional surgery.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101727"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146004910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excess burden of hospitalizations in adults with diabetes – a national US cross-sectional study","authors":"Jessica L Harding ,&nbsp;Tegveer S Uppal ,&nbsp;Dunya Tomic ,&nbsp;Mohammed K Ali ,&nbsp;Agus Salim ,&nbsp;Dianna J Magliano","doi":"10.1016/j.diabet.2026.101726","DOIUrl":"10.1016/j.diabet.2026.101726","url":null,"abstract":"<div><h3>Objective</h3><div>The true burden of diabetes is likely underestimated by not considering the full range of complications associated with diabetes. Our aim was to compare cause-specific hospitalizations in adults with vs. without diabetes.</div></div><div><h3>Research Design and Methods</h3><div>Our denominator included all adults with and without self-reported diabetes from the 2019 Behavioral Risk Factor Surveillance System Survey, weighted to reflect the U.S. population. Our numerator, age-standardized risks of ICD-10-CM-defined inpatient hospitalizations and emergency department (ED) visits, were identified from the 2019 National Inpatient Sample and National ED Sample, respectively, weighted to be representative of U.S. hospitalizations. Each cause-specific hospitalization was classified as traditional, emerging, or other.</div></div><div><h3>Results</h3><div>For inpatient hospitalizations, the highest absolute risk difference per classification was for sepsis (traditional; 1,680 [95%CI: 1,649–1,712] hospitalizations per 100,000), pneumonia (emerging; 225 [218–232]), and respiratory failure (other; 280 [272–289]). For ED visits, the highest absolute risk difference was for abscess, furuncle, and carbuncle (traditional; 388 [352–423] visits per 100,000), complications of cardiac devices (emerging; 111 [104–118]), and disorders of the urinary system (other; 299 [252–346]).</div></div><div><h3>Conclusions</h3><div>The causes of excess hospitalizations associated with diabetes extend well beyond traditional complications with implications for population-level planning, resource allocation, and individual diabetes management.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101726"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145975427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Half the genome, half the story? Paternal metabolic health and offspring outcomes in the era of modern obesity pharmacotherapy","authors":"Theocharis Koufakis ,&nbsp;Vasileios Tsimihodimos ,&nbsp;Djordje S. Popovic","doi":"10.1016/j.diabet.2026.101743","DOIUrl":"10.1016/j.diabet.2026.101743","url":null,"abstract":"<div><div>Research on the developmental origins of health and disease has traditionally centered on maternal health and in utero exposures, with comparatively limited attention to paternal preconception factors. However, emerging evidence suggests that paternal metabolic health—particularly obesity and diabetes—may contribute to offspring metabolic risk. Observational studies associate higher paternal body mass index and cardiometabolic dysfunction with increased offspring adiposity, blood pressure, and markers of insulin resistance, although effect sizes are modest and confounding by shared genetics and environment remains a key limitation. Mechanistic data from animal models support sperm-mediated epigenetic pathways linking paternal metabolic status to offspring metabolic programming, yet human epigenetic evidence is inconsistent. At the same time, the widespread use of modern obesity pharmacotherapies, including glucagon-like peptide-1 receptor agonists and dual incretin agonists, has introduced a largely unexamined dimension of paternal exposure. Current data on paternal use of these agents and long-term offspring metabolic outcomes are sparse and fragmentary. As obesity pharmacotherapy expands among men of reproductive age, a shift beyond maternal-only frameworks is warranted. Rigorous studies integrating paternal metabolic profiling, medication exposure, and long-term offspring follow-up are urgently needed to inform clinical practice and public health guidance.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101743"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA-guided identification of monogenic diabetes in antibody-negative type 1 diabetes: frequency and characteristics","authors":"Yan Chen ,&nbsp;Min Yin ,&nbsp;Yuting Xie ,&nbsp;Chao Deng ,&nbsp;Zhiguo Xie ,&nbsp;Gan Huang ,&nbsp;Shuoming Luo ,&nbsp;Zhiguang Zhou ,&nbsp;Xia Li","doi":"10.1016/j.diabet.2026.101741","DOIUrl":"10.1016/j.diabet.2026.101741","url":null,"abstract":"<div><h3>Aims</h3><div>Antibody-negative type 1 diabetes (T1D) is a provisional diagnosis with unclear etiology. This study aimed to determine the prevalence and phenotypic characteristics of monogenic diabetes within a large antibody-negative T1D cohort.</div></div><div><h3>Methods</h3><div>A total of 482 antibody-negative T1D patients were included from a clinically diagnosed T1D cohort. Targeted sequencing using a custom gene panel covering 36 genes and the mitochondrial 3243 <em>A</em> &gt; <em>G</em> mutation was performed. Demographic, metabolic, and human leukocyte antigen (HLA) data were analyzed. Beta-cell function was assessed in patients with monogenic diabetes amenable to precision treatment.</div></div><div><h3>Results</h3><div>Among 482 antibody-negative T1D patients, 2.5% (12/482) had maturity-onset diabetes of the young (MODY) and 1.7% (8/482) had mitochondrial diabetes. The prevalence of MODY increased to 11.1% (6/54) among childhood-onset patients with a single susceptible HLA haplotype, while mitochondrial diabetes reached 6.2% (7/113) in adult-onset patients lacking HLA-susceptible haplotypes. Other characteristics, including gender, age at diagnosis, hemoglobin A1c, 2-hour postprandial C-peptide (2hCP), and family history of diabetes, showed no significant differences. Compared with the “truly” antibody-negative T1D group, MODY patients had an earlier onset, whereas mitochondrial diabetes patients had later onset, higher 2hCP, and fewer HLA-susceptible haplotypes (all <em>P</em> &lt; 0.05). Of eight recalled monogenic diabetes patients, 62.5% (5/8) retained random C-peptide &gt; 100 pmol/L after a median 15.7 years.</div></div><div><h3>Conclusions</h3><div>In antibody-negative T1D, MODY and mitochondrial diabetes accounted for 2.5% and 1.7%, respectively. HLA genotype was the key distinguishing factor. Persistent C-peptide secretion in monogenic diabetes supports the need for genetic screening in antibody-negative T1D patients.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101741"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors impacting the recent doubling of French hyperglycaemia prevalence in pregnancy","authors":"Élodie Lebreton ,&nbsp;Luveon Tang ,&nbsp;Sandrine Fosse-Edorh ,&nbsp;Anne Vambergue ,&nbsp;Emmanuel Cosson ,&nbsp;Nolwenn Regnault","doi":"10.1016/j.diabet.2026.101724","DOIUrl":"10.1016/j.diabet.2026.101724","url":null,"abstract":"<div><h3>Aim</h3><div>To assessed hyperglycaemia in pregnancy (HIP) prevalence trends over the past decade, accounting for risk factors and screening practices (France introduced early risk-based HIP screening in 2010).</div></div><div><h3>Methods</h3><div>We analysed national delivery data from the French National Health Data System (SNDS) (2012-2022), excluding women with pre-existing diabetes (n=8,172,911). Poisson regressions with generalized estimating equations estimated prevalence ratios (PR) for HIP risk factors. Counterfactual scenarios quantified contributions of maternal age, early screening, and pre-pregnancy overweight to HIP increase.</div></div><div><h3>Results</h3><div>HIP prevalence increased from 7.5% in 2012 to 15.7% in 2022, with early HIP tripling. Prevalence rose in 2020–2021 during the Covid-19 pandemic. After adjustment for maternal age, parity, socioeconomic status, season of pregnancy onset, place of delivery, regional prevalence of pre-pregnancy overweight, and early screening, the aPR were 1.30 [1.11–1.51] in 2021 and 1.15 [0.97–1.36] in 2022 vs. 2012 (unadjusted: 2.24 [2.22–2.26] and 2.08 [2.06–2.10]), suggesting that these factors account for a large proportion of the observed increase. While the observed increase in HIP prevalence was 8.2 percentage points from 2012 to 2022, counterfactual scenarios estimated increases of 6.5 [5.9–7.3] for constant maternal age, 6.2 [5.1–7.7] for constant early screening (13.7%), and 4.3 [2.4–5.9] for constant regional pre-pregnancy overweight (11.8%) at 2012 levels.</div></div><div><h3>Conclusion</h3><div>Rising maternal age, increased early HIP screening, and higher regional pre-pregnancy overweight prevalence mostly contributed to HIP prevalence increase. Public health strategies should prioritize modifiable risk factors—particularly pre-pregnancy overweight—and evaluate the effectiveness of early screening practices.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101724"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}